Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Multimodal Imaging of Choroidal Lymphoma: Diagnostic Features, Differential Diagnosis, and Clinical Monitoring.

Ocular immunology and inflammation·2026
Same author

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same author

Disseminated <i>Mycobacterium haemophilum</i> Infection Complicating Immunosuppressive Therapy in HLA-A29 Positive Birdshot Chorioretinopathy: Case Report.

Case reports in ophthalmology·2026
Same author

Pathways to Patchy Atrophy in High Myopia: Precursor Patterns, Structural Characteristics, and Long-Term Outcomes.

Ophthalmology science·2026
Same author

Unfolding the Pitchfork Sign in Type 2 Choroidal Neovascularization: A Longitudinal Analysis and 3-Dimensional Reconstructions.

Ophthalmology science·2026
Same author

Advanced Multimodal Imaging in Granulomatous Uveitis: From Differential Diagnosis to Treatment Monitoring and Surgical Integration.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Nov 17, 2025

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

569

Drug-induced Sarcoid Uveitis with Biologics.

Bianka Sobolewska1, Edoardo Baglivo2, Albert O Edwards3

  • 1Center of Ophthalmology, University of Tuebingen, Tuebingen, Germany.

Ocular Immunology and Inflammation
|February 17, 2021
PubMed
Summary
This summary is machine-generated.

Biologic agents can trigger new or recurring uveitis (eye inflammation). This condition often presents as granulomatous disease, particularly sarcoid uveitis, in patients with autoimmune disorders.

Keywords:
Biologic agentsanti-TNF therapysarcoidosisuveitis

More Related Videos

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.5K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.4K

Related Experiment Videos

Last Updated: Nov 17, 2025

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

569
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.5K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.4K

Area of Science:

  • Ophthalmology
  • Rheumatology
  • Immunology

Background:

  • Biologic agents are increasingly used to treat autoimmune and inflammatory conditions.
  • Uveitis, or intraocular inflammation, can be a side effect of systemic therapies.
  • Understanding drug-induced uveitis is crucial for patient management.

Purpose of the Study:

  • To evaluate new-onset or reactivated uveitis in patients receiving biologic agents.
  • To characterize the clinical features of biologic treatment-induced uveitis.

Main Methods:

  • A multicenter, retrospective case series.
  • Inclusion criteria: patients on biologic therapy who developed new uveitis or a change in previous uveitis pattern.
  • Data collected on underlying conditions, biologic agents, and uveitis characteristics.

Main Results:

  • Sixteen patients were identified with uveitis associated with biologic therapy.
  • Common underlying conditions included ankylosing spondylitis, juvenile idiopathic arthritis, rheumatoid arthritis, and Behçet's Disease.
  • Biologic agents implicated: etanercept, adalimumab, abatacept, infliximab, and golimumab. Five patients were diagnosed with sarcoidosis, and seven others showed features suggestive of sarcoid uveitis.

Conclusions:

  • Biologic treatment-induced uveitis frequently manifests as a granulomatous condition.
  • Sarcoid uveitis is a notable presentation in patients on certain biologic therapies.
  • Early recognition and characterization are key for managing this adverse event.